Menu
Search
|

Menu

Close
X

argenx NV ARGX.OQ (NASDAQ Stock Exchange Global Select Market)

80.11 USD
-0.96 (-1.18%)
As of Feb 16
chart
Previous Close 81.07
Open 80.74
Volume 47,962
3m Avg Volume 51,208
Today’s High 80.74
Today’s Low 79.76
52 Week High 87.00
52 Week Low 17.42
Shares Outstanding (mil) 32.17
Market Capitalization (mil) 2,058.93
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.25 Mean rating from 4 analysts

KEY STATS

Revenue (mm, EUR)
FY17
28
FY16
20
FY15
9
EPS (EUR)
FY17
-0.599
FY16
-1.375
FY15
-1.168
*Note: Units in Millions of Euro
**Note: Units in Euro

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
34.43
Price to Sales (TTM)
vs sector
63.12
8.57
Price to Book (MRQ)
vs sector
--
5.14
Price to Cash Flow (TTM)
vs sector
--
25.75
Total Debt to Equity (MRQ)
vs sector
--
15.12
LT Debt to Equity (MRQ)
vs sector
--
11.85
Return on Investment (TTM)
vs sector
--
13.54
Return on Equity (TTM)
vs sector
--
14.80

EXECUTIVE LEADERSHIP

Peter Verhaeghe
Chairman of the Supervisory Board, Since
Salary: --
Bonus: --
Tim Van Hauwermeiren
Chief Executive Officer, Since
Salary: --
Bonus: --
Eric Castaldi
Chief Financial Officer, Since
Salary: --
Bonus: --
Hans de Haard
Chief Scientific Officer, Since
Salary: --
Bonus: --
Debbie Allen
Senior Director, Business Development, Since
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

Willemstraat 5
BREDA     4811 AH

Phone: +3176.3030488

argenx NV, formerly arGEN X BV is the Netherlands-based biopharmaceutical company. It creates and develops a pipeline of differentiated antibody therapeutics using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The Company develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. It includes: ARGX-110, an antibody for heme malignancies and solid tumors, which modulates functions of tumor such as cell proliferation and survival; ARGX-111, an antagonist of c-Met, a receptor tyrosine kinase involved in cell proliferation, angiogenesis and metastasis in multiple solid tumors; ARGX-112, an antigen which targets atopic dermatitis by neutralization of IL-20 and IL-22 (interleukin) mediated signaling through blockade of their common receptor, among others.

SPONSORED STORIES